In one of the phase II clinical trials, administration of cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, promotes a rapid and prolonged vascular normalization in GBs patients. The gene discussed is VEGFA; the disease is Guillain-Barre syndrome.